{"entity":{"id":"century-therapeutics","kind":"company","name":"Century Therapeutics","aka":[],"tldr":"Century makes off-the-shelf cell therapies from induced pluripotent stem cells that are engineered to hide from the patient's immune system. Its main focus is now type 1 diabetes, with a CD19 CAR T-like product for cancer and autoimmune disease due to enter the clinic in 2026.","summary":"Century Therapeutics develops allogeneic, induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune disease and cancer. Lead programme CNTY-813 is an iPSC-derived islet replacement therapy for type 1 diabetes with an IND submission planned for the fourth quarter of 2026 following a pre-IND meeting with the FDA. CNTY-308 is a CD19-targeted CAR-iT (iPSC-derived T cell) therapy incorporating the company's Allo-Evasion 5.0 immune-evasion edits, on track to enter the clinic in 2026. The company reported $197.2 million in cash and investments at 30 June 2026 with runway into the first quarter of 2029. Century is headquartered in Philadelphia and trades on Nasdaq as IPSC.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.centurytx.com/"},{"label":"Q2 2026 results (8-K exhibit 99.1)","url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465926094533/tm2622911d1_ex99-1.htm"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["allogeneic-cell-therapy","car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Strategic emphasis has shifted to type 1 diabetes; oncology exposure is via CNTY-308 (CD19 CAR-iT). IPO round not sourced (June 2021 8-K did not state proceeds)."],"hq":"Philadelphia, PA","country":"US","companyType":"cell-therapy","website":"https://www.centurytx.com/","ticker":"IPSC","stage":"public","investors":["leaps-by-bayer"],"funding":[]},"route":"/companies/century-therapeutics/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"},{"id":"allogeneic-cell-banks","kind":"technology","name":"Allogeneic cell banks: one donor, hundreds of doses","route":"/technologies/allogeneic-cell-banks/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"company":[{"id":"leaps-by-bayer","kind":"company","name":"Leaps by Bayer","route":"/companies/leaps-by-bayer/"}]}}